Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2010
11/24/2010CN101889998A Composition and application thereof as TR3 receptor inducer
11/24/2010CN101889975A Rosuvastatin calcium sustained-release preparation and preparation method thereof
11/24/2010CN101889953A Device and method for manufacturing drug smoke liquid and drug smoke
11/24/2010CN101889687A Selenium-enriched white red-rooted salvia root tea and preparation method thereof
11/24/2010CN101889680A Health care product with weight losing function
11/24/2010CN101889636A Composition used for mammal's diet and method for controlling the rate of hair growth
11/24/2010CN101259115B Orally-administered insulin soft capsule for treating diabetes and preparation thereof
11/24/2010CN101215324B Exenatide short peptide simulation peptide and application thereof in preparing medicament for curing diabetes
11/24/2010CN101204573B Medicine foe diabetes mellitus
11/24/2010CN101199504B Function of stilbene oxygen acid or salt in preparing antiatheroscloresis medicament
11/24/2010CN101139393B KDR peptides and vaccines containing the same
11/24/2010CN101049297B High DNA type fatty ethyl ester in high purity, manufacturing method and preparation
11/24/2010CN101045715B Heterocycle inhibitor for glycogen synthase kinase gsk-3
11/23/2010US7838682 Glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
11/23/2010US7838644 oversulfation of epiK-N sulfate to obtain an epiK5-amine-O-oversulfate with very high sulfation degree which by subsequent N-sulfation provides new epiK5-N,O-oversulfate-derivatives; free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field
11/23/2010US7838565 Suppresses reduction in peripheral nerve conduction rate and alleviates hypofunction of bladder so that it is useful as a preventive and/or therapeutic agent for, particularly, diabetic neuropathy
11/23/2010US7838555 Useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and
11/23/2010US7838554 dyslipidemia; regulating lipid, lipoprotein, insulin, glucose levels in the blood; 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid; 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol; 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; 2,2,14,14-Tetramethyl-pentadecane-1,6,10,15-tetraol
11/23/2010US7838541 Methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
11/23/2010US7838529 type II diabetes mellitus and obesity; dipeptidylpeptidase-IV (DPP-IV) inhibitor; 1-[2-(2-formylaminophenyl)-2-oxoethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine (xanthine=3,7-dihydro-purine-2,6-dione)
11/23/2010US7838528 Substituted bicyclic 8-pyrrolidinoxanthines, methods for their production, pharmaceutical formulations and their use
11/23/2010US7838525 modulators of glucose metabolism, GPCR, RUP3; metabolic disorders and complications thereof such as diabetes and obesity; 4-[5-Cyano-6-(6-methylsulfanyl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid tert-butyl ester
11/23/2010US7838289 Assay utilizing multipotent adult stem cells
11/23/2010US7838043 administering scavenger of superoxide anion or nitric oxide comprising fine powder of platinum (colloid) which is prepared by metal salt reduction in presence of water-soluble polymer comprising polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, cyclodextrin, amylopectin, and methylcellulose
11/23/2010US7838037 of active ingredients for topical use; dissolving active ingredient in ethyl acetate with acrylate copolymer; double-layer and triple-layer microcapsules; oxidation resistance; storage stability
11/23/2010CA2459380C Reverse hydroxamic acid derivatives
11/23/2010CA2438870C Novel inhibitors of formation of advanced glycation endproducts (ages)
11/23/2010CA2377309C Compounds for the modulation of ppar.gamma. activity
11/23/2010CA2354148C Aerosol formulations for buccal and pulmonary application
11/23/2010CA2169292C Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
11/18/2010WO2010132882A2 Sublingual dexmedetomidine compositions and methods of use thereof
11/18/2010WO2010132580A2 Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
11/18/2010WO2010132562A2 Transdermal delivery of metformin
11/18/2010WO2010132502A2 Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
11/18/2010WO2010132389A2 Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
11/18/2010WO2010131718A1 Anti-hyperglycemic and/or anti-hyperlipidemic agent comprising material containing avian skin-derived sphingomyelin as active ingredient
11/18/2010WO2010131704A1 Test agent for visceral obesity and use thereof
11/18/2010WO2010131703A1 NOVEL PPARγ PROMOTER SEQUENCE AND USE APPLICATION THEREOF
11/18/2010WO2010131695A1 Modified double-stranded rna
11/18/2010WO2010131669A1 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof
11/18/2010WO2010131491A1 Method and kit for evaluation of predisposition to development of obesity, anti-obesity agent and method for screening thereof, non-human animal, adipose tissue, adipocyte, method for production of transgenic mouse, antigen, and antibody
11/18/2010WO2010131191A1 Thiazolidin-4-one and [1,3]-thiazinan-4-one compounds as orexin receptor antagonists
11/18/2010WO2010131035A1 Novel crystalline polymorph of sitagliptin dihydrogen phosphate
11/18/2010WO2010131025A1 Sitagliptin synthesis
11/18/2010WO2010130799A2 Method for impregnation with supercritical co2
11/18/2010WO2010130779A2 COMBINATION OF A PBOSPBOINOSITKLE 3-KSπASE INHIBITOR AND AN ANTIDIABETIC COMPOUND
11/18/2010WO2010130771A2 Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes
11/18/2010WO2010130665A1 Azacyclic spiroderivatives as hsl inhibitors
11/18/2010WO2010130152A1 Pharmaceutical composition for treating cardiovascular disorder and use thereof
11/18/2010WO2010111626A3 Poly (adp-ribose) polymerase (parp) inhibitors
11/18/2010WO2010107177A3 Composition for prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredients
11/18/2010WO2010102171A3 Secreted ap2 and methods of inhibiting same
11/18/2010WO2010092218A3 Use of cardiotrophin- 1 for the treatment of metabolic diseases
11/18/2010WO2010083280A3 Methods for treating obesity and disorders associated with hyperlipidemia in a mammal
11/18/2010WO2010083279A3 Methods for treating disorders associated with hyperlipidemia in a mammal
11/18/2010WO2010065879A9 Methods of treating an overweight or obese subject
11/18/2010WO2010036613A8 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
11/18/2010WO2010014541A3 Compositions and methods for treatment of hypercholesterolemia
11/18/2010US20100292650 Methods and Related Compositions for Reduction of Fat and Skin Tightening
11/18/2010US20100292500 Npy y5 antagonist
11/18/2010US20100292345 Therapeutic uses of cannabigerol
11/18/2010US20100292339 Genetic Polymorphisms Predictive of Nutritional Requirements for Choline in Subjects
11/18/2010US20100292334 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors
11/18/2010US20100292320 Benzofuran anilide histone deacetylase inhibitors
11/18/2010US20100292296 Novel ligands that modulate rar receptors
11/18/2010US20100292289 Treatment of metabolic syndrome with novel amides
11/18/2010US20100292288 Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
11/18/2010US20100292282 Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
11/18/2010US20100292277 Combination treatment of metabolic disorders
11/18/2010US20100292273 Cannabinoid Receptor Modulators
11/18/2010US20100292271 Quinoline Compounds Suitable for Treating Disorders that Respond to Modulation of the Serotonin-5-HT6 Receptor
11/18/2010US20100292270 Treatment of cachexia
11/18/2010US20100292259 Pyrimidyl indoline compound
11/18/2010US20100292256 (EN) 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO [1,5-A]PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF
11/18/2010US20100292254 Fused Pyrimidine Derivatives as Trpv3 Modulators
11/18/2010US20100292250 CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF
11/18/2010US20100292245 (en) substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
11/18/2010US20100292240 Sulfonamide compounds
11/18/2010US20100292238 Phenoxymethyl Heterocyclic Compounds
11/18/2010US20100292235 Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
11/18/2010US20100292234 Triazole fused heteroaryl compounds and methods of use thereof
11/18/2010US20100292233 Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists
11/18/2010US20100292225 Aryl pyridine as aldosterone synthase inhibitors
11/18/2010US20100292221 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/18/2010US20100292220 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
11/18/2010US20100292215 11beta-hydroxysteroid dehydrogenase type 1 active compounds
11/18/2010US20100292212 New azacyclic derivatives
11/18/2010US20100292208 Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
11/18/2010US20100292206 Heterocyclic compound
11/18/2010US20100292205 Pyrimidone Compounds As GSK-3 Inhibitors
11/18/2010US20100292204 Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
11/18/2010US20100292188 Compounds Comprising A Cyclobutoxy Group
11/18/2010US20100292178 Method of treating non-insulin dependent diabetes mellitus and related complications
11/18/2010US20100292171 Competitive Regulation of Hepcidin mRNA by Soluble and Cell-Associated Hemojuvelin
11/18/2010US20100292169 Methods and compositions for regulating hdac6 activity
11/18/2010US20100292144 Sustained delivery of exenatide and other peptides
11/18/2010US20100292143 Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
11/18/2010US20100292142 Novel neurotrophic factors
11/18/2010US20100292141 Insulin nasal powder inhalation
11/18/2010US20100292133 Truncated glp-1 derivaties and their therapeutical use
1 ... 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 ... 1298